breaux castleman  isis pharmaceuticals  inc  zoominfocom page not found  thestreet action alerts plus access aapjim cramers best stocks for charitable trust portfoliomost recent trade alert investing rules trading commandments real money access rm rules of investingjim cramers best stocks for  commandmentsstressed out stockscramers blog cramer mad money etfs futures markets much more banksbiotechretailtechpersonal financeretirementfinancial advisor centerhow to spendoptionsfixed incomevideo privacy policyterms of use  thestreet inc all rights reserved djia nasdaq sp  market data updated sign in your memberships your account account preferences alerts newsletters subscribe logout subscribe access insights and guidance from our wall street pros find the product thats right for you action alerts plus action alerts options daily swing trade income seeker quant ratings real money real money pro stocks under  top stocks trifecta stocks real money pro portfolio chairmans club compare all chatter on the street page not found sorry the page youre looking for is not available you might want to try our homepage our most popular stories  thestreet inc all rights reservedaction alerts plus is a registered trademark of thestreet inc compare brokers breaux castleman syntiro healthcare services inc profile  biography  bloomberg feedback breaux castleman chairmanpresidentceo syntiro healthcare services inc career history chairmanpresidentceo syntiro healthcare services inc present senior advisor mcnally capital llc present chairmanconsultant mela sciences inc 0 chairmanconsultant electrooptical sciences inc 0 president scripps clinic  presphysician resource caremark intl inc  chief executive officer kelseyseybold clinic 999 senior advisor match point partners llc former headhouston office booz  co former show more corporate information address 9 echo lane suite 44 houston tx 4 united states phone 343 fax  from the web personal information education yale university bachelors degree economics memberships board memberships fempartners inc board member present nextcare inc board member present meddirect inc board member present ionis pharmaceuticals inc board member 0present usmd holdings inc board member present syntiro healthcare services inc chairman present isis pharmaceuticals inc board member 030 mela sciences inc chairman 0 electrooptical sciences inc chairman 0 show more sponsored financial commentaries more from the web home news top headlines most popular exclusive law entrepreneurs leaders economy environment science sports markets magazine pursuits magazine bloomberg visual data bloomberg best and worst for comments or complaints about news coverage click here regions us china europe asia uk  ireland australia  new zealand canada india  pakistan japan africa eastern europe latin america middle east markets commodities currencies bonds stocks energy markets municipal bonds emerging markets funds islamic finance industries energy technology real estate finance health care transportation insurance retail media manufacturing quick market data stocks stock futures world indexes americas europe middle east  africa asiapacific gainers  losers earnings calendar industry leaders currencies americas europe middle east  africa asiapacific foreign exchange cross rates fx fixings currency converter forex trading videos commodities energy prices metals prices agricultural prices rates  bonds us treasuries uk gilts germany bunds japan bonds australia bonds bloomberg bond indexes corporate bonds consumer rates economic calendar watchlist european debt crisis symbol search the market now personal finance top headlines saving  investing real estate retirement planning financial advisers taxes blog ventured  gained real cost of money gallery calculators watchlist portfolio tracker tech top headlines social media mobile  wireless web enterprise tech tv games  movies apple tech deals global tech slideshows videos us politics sustainability top headlines energy corporate sustainability policy natural resources health  population slideshows videos blog the grid luxury top headlines autos billionaires living property travel well spent loot blog pursuits magazine videos tv live tv channel finder personalities apple tv ipad app schedule us asia europe shows surveillance market makers lunch money street smart bloomberg west game changers video must see latest live tv shows playlist radio live radio shows schedule personalities podcasts bloomberg brief featured podcasts and new shows bloomberg view masters in business first word surveillance bloomberg advantage in the loop bloomberg law taking stock bloomberg best more podcasts blogs global tech the grid loot the market now political capital tech deals ventured and gained opinion my saved registration sign in bloombergcom businessweekcom company about blog careers diversity  inclusion news mission philanthropy  engagement press room procurement sustainability products financial products bloomberg professional service bloomberg anywhere bloomberg tradebook bloomberg briefs bloomberg indexes bloomberg sef service center customer support enterprise products enterprise solutions trading solutions industry products bloomberg bna bloomberg government bloomberg law bloomberg link bloomberg new energy finance bloomberg sports content licensing bloomberg anywhere mobile apps bloomberg visual data   forbidden access is denied server error   forbidden access is denied you do not have permission to view this directory or page using the credentials that you supplied breaux castleman joins isis pharmaceuticals’ board of directors breaux castleman joins isis pharmaceuticals board of directors jun  03 0 et from isis pharmaceuticals inc carlsbad calif june  03 prnewswire  isis pharmaceuticals inc nasdaq isis announced today that breaux castleman has joined the companys board of directors  mr castleman is president and chief executive officer of syntiro healthcare services inc a health care investment company which recently sold its operations as a service provider of integrated care management and disease management  mr castleman is also a director of usmd holdings inc and a senior advisor to mcnally capital llc in chicago we are very pleased to have breaux join our board  breaux has held executive positions in some of the nations leading managed care provider organizations and has been a pioneer in creating innovative solutions to deliver value in the healthcare sector  his successful enterprises in the medical industry have also provided him with a broad base of experience in delivering medicines to patients and productively working with payors said stanley t crooke md phd chairman and chief executive officer of isis  breaux leadership and sound business judgment will be valuable to isis as we continue to successfully implement our business strategy and evaluate opportunities within our pipeline to retain some of our drugs to later stages in development thereby retaining a larger portion of the commercial upside of these drugs mr castleman also serves as a director of fempartners inc and a senior advisor to match point partners llc in new york previously he held positions as chairman of mela sciences inc director of med direct inc president of the scripps clinic president of caremark internationals physician resource group and chief executive officer of the kelseyseybold clinic  prior to that mr castleman was the head of the houston office of booz allen  hamilton now booz  co mr castleman received a ba in economics from yale university and attended new york university graduate school of business administration he has published articles on management issues in business and technical periodicals including the harvard business review and has presented numerous papers and presentations to industry groups in energy banking healthcare and agribusiness about isis pharmaceuticals inc isis is exploiting its leadership position in antisense technology to discover and develop novel drugs for its product pipeline and for its partners  isis broad pipeline consists of  drugs to treat a wide variety of diseases with an emphasis on cardiovascular metabolic severe and rare diseases and cancer  isis partner genzyme is commercializing isis lead product kynamro™ in the united states for the treatment of patients with hofh  genzyme is also pursuing marketing approval of kynamro in other markets  isis patents provide strong and extensive protection for its drugs and technology  additional information about isis is available at wwwisispharmcom isis pharmaceuticals forwardlooking statement this press release includes forwardlooking statements regarding isis pharmaceuticals business and the commercial potential of isis technologies and products in development  any statement describing isis goals expectations financial or other projections intentions or beliefs including the commercial potential of kynamro is a forwardlooking statement and should be considered an atrisk statement  such statements are subject to certain risks and uncertainties particularly those inherent in the process of discovering developing and commercializing drugs that are safe and effective for use as human therapeutics and in the endeavor of building a business around such drugs  isis forwardlooking statements also involve assumptions that if they never materialize or prove correct could cause its results to differ materially from those expressed or implied by such forwardlooking statements  although isis forwardlooking statements reflect the good faith judgment of its management these statements are based only on facts and factors currently known by isis  as a result you are cautioned not to rely on these forwardlooking statements  these and other risks concerning isis programs are described in additional detail in isis annual report on form k for the year ended december 3 0 and its most recent quarterly report on form q which are on file with the sec copies of these and other documents are available from the company in this press release unless the context requires otherwise isis company we our and us refers to isis pharmaceuticals and its subsidiaries isis pharmaceuticals® is a registered trademark of isis pharmaceuticals inc  kynamro™ is a trademark of genzyme corporation source isis pharmaceuticals inc related links httpwwwisispharmcom view table fullscreen view table fullscreen jul  03 0 et preview isis pharmaceuticals to present at the th annual jmp securities healthcare conference jun  03 3 et preview isis reports phase  data on isisapociii rx showing significant reductions in triglycerides and apociii in patients with high triglycerides and type  diabetes my news release contains wide tables view fullscreen search searching for your content advanced search breaux castleman « match point partners search for breaux castleman advisory board member mr castleman brings a wealth of leadership experience to the match point team having held executive positions in some of the nation’s leading managed care companies he is currently the president and ceo of syntiro healthcare services inc a business process out sourcing care management and disease management company previously mr castleman was president of the scripps clinic in lajolla was president of caremark international’s physician resource division in chicago was ceo of the kelseyseybold clinic in houston and was a partner of booz allen  hamilton in houston he is currently a director of usmd holdings inc nasdaq usmd an integrated delivery system in dallasfort worth and a director of isis pharmaceuticals a drug development company and a senior advisor to mcnally capital llc in chicago a private equity advisor firm in the past he was chairman of mela sciences inc nasdaq mela a director of nextcare inc an urgent care clinic operator director of med direct inc a revenue cycle management service company mr castleman was graduated from yale university with a degree in economics and resides in houston and washington dc    go back home our firm services our team experience media contact us new york washington dc san francisco securities offered through manor park securities llc member finra  sipc 0 match point partners llcall rights reserved breaux castleman — mcnally capital breaux castleman senior advisor mr castleman was president and ceo of syntiro healthcare services inc a business process outsourcing care management and disease management company prior to that breaux was ceo of physia corporation which developed physician practice management software breaux also served as president and coo of the scripps clinic a 3physician multispecialty medical group practice in san diego breaux was president of the physician resources division of caremark international in chicago where through acquisition of physician practices he grew the business from 0m in revenue to m and effected acquisitions in  states with a notional value in excess of 40m prior to that breaux was ceo of the kelseyseybold clinic in houston a 4physician multispecialty medical group with 4 locations before entering healthcare breaux was the partner in charge of the houston office of booz allen hamilton consulting to the energy banking and specialty chemicals business he is currently a director of fempartners inc a physician practice management company in houston and chairman of electrooptical sciences inc nasdaq mela a developmentstage diagnostic medical device company in irvington ny breaux is a board director of usmd holdings inc a physician practice management company in dallas which coordinates care across physicians hospitals and other specialty practices to create an integrated care platform  breaux is also on the board of advanced micro instruments a portfolio company of mcnally capital breaux received a ba in economics from yale university and attended new york university graduate school of business administration he has published articles on management issues in business and technical periodicals including the harvard business review and has presented numerous papers and presentations to industry groups in energy banking healthcare and agribusiness   forbidden access is denied server error   forbidden access is denied you do not have permission to view this directory or page using the credentials that you supplied